40,114 Shares of Regeneron Pharmaceuticals, Inc. $REGN Purchased by Smith Group Asset Management LLC

Smith Group Asset Management LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 40,114 shares of the biopharmaceutical company’s stock, valued at approximately $30,417,000. Regeneron Pharmaceuticals makes up approximately 2.0% of Smith Group Asset Management LLC’s holdings, making the stock its 24th biggest position.

A number of other large investors have also recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $11,358,000. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $5,682,636,000. Contravisory Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $6,327,000. Oxbow Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $3,342,000. Finally, Deutsche Bank AG acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $323,249,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. HSBC raised their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Jefferies Financial Group boosted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $847.90.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider Andrew Murphy sold 4,147 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $813.27 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The company has a market capitalization of $83.73 billion, a PE ratio of 20.10, a P/E/G ratio of 1.36 and a beta of 0.16. The company has a fifty day moving average of $791.72 and a two-hundred day moving average of $737.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $12.81 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.